By Ben Glickman

Novartis received approval from the Food and Drug Administration for its intravenous formulation of Cosentyx, its treatment for psoriatic arthritis and other conditions.

The pharmaceutical company said the IV delivery option would be available in the fourth quarter.

Cosentyx, which goes by generic name secukinumab, can be used to treat psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis.

Novartis said the treatment available in IV form to block the specific interleukin-17A, which causes inflammation associated with certain diseases.

The company said the IV formulation would be monthly and would take 30 minutes to administer. Novartis said the dosing option does not require lab monitoring or pre-medication.

In the second quarter, Cosentyx brought in $1.27 billion in sales for Novartis.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

October 06, 2023 16:56 ET (20:56 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Novartis 차트를 더 보려면 여기를 클릭.
Novartis (NYSE:NVS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Novartis 차트를 더 보려면 여기를 클릭.